Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BASF is planning to relocate the pharmaceutical production of its Kolliphor TPGS (Speziol TPGS Pharma, vitamin E polyethylene glycol succinate), from its Kankakee, US, site to Minden, Germany, facility.
Subscribe to our email newsletter
Kolliphor TPGS is a water-soluble derivative of vitamin E that can directly improve the bioavailability of poorly soluble active substances.
BASF Global Business Unit Pharma Ingredients & Services Global Marketing New Products head Thorsten Schmeller said the relocation creates a centralized production facility, reducing complexity in the production setup, while providing room for future expansion.
The company said until the production in Minden is fully operational, it will continue to manufacture Kolliphor TPGS at the Kankakee site.
Kolliphor TPGS is commonly used in pharmaceutical and nutritional, as well as in cosmetic formulations.
The production of Kolliphor TPGS at the Minden site is likely to begin in the first quarter of 2013 with the completion scheduled to Q1, 2014.